What % of GILD’s $98M QoQ decline in 3Q18 HCV sales was due to each of the following: a) Fewer HCV patients treated; b) Lower ASP; c) Loss of market share to Mavyret?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”